{"transactions":[{"id":2481849,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:10:11.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":206434,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\").  In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac.  After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee.  The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein."}],"balance_after":206434,"source":{"system":"sec-edgar","filing":"0000899243-21-047222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924321047222/doc4.xml","form_type":"4"}},{"id":2481848,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:10:11.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":274930,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\").  In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac.  After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee.  The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein."}],"balance_after":274930,"source":{"system":"sec-edgar","filing":"0000899243-21-047222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924321047222/doc4.xml","form_type":"4"}},{"id":2481847,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:10:11.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":3018644,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\").  In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac.  After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee.  Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac.  The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein."}],"balance_after":3018644,"source":{"system":"sec-edgar","filing":"0000899243-21-047222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924321047222/doc4.xml","form_type":"4"}},{"id":2482276,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:09:47.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":7373,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decedents Trust except to the extent of his pecuniary interest therein."}],"balance_after":7373,"source":{"system":"sec-edgar","filing":"0001019056-21-000634","document":"elhibri.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000634/elhibri.xml","form_type":"4"}},{"id":2482275,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:09:47.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":9819,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Family Trust except to the extent of his pecuniary interest therein."}],"balance_after":9819,"source":{"system":"sec-edgar","filing":"0001019056-21-000634","document":"elhibri.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000634/elhibri.xml","form_type":"4"}},{"id":2482274,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-08T02:09:47.000Z","date":"2021-12-03","kind":"other","acquired":true,"shares":107807,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company (\"Intervac\"), and BioVac, L.L.C., a Maryland limited liability company (\"BioVac\"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the \"Distribution\"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 5,880 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 59,253 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 48,554 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein."}],"balance_after":107807,"source":{"system":"sec-edgar","filing":"0001019056-21-000634","document":"elhibri.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000634/elhibri.xml","form_type":"4"}},{"id":2686612,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-06-02T23:33:16.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units (the \"RSUs\") convert into shares of the Issuer's common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in three approximately equal annual installments beginning on June 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in three approximately equal annual installments beginning on June 1, 2022."}],"balance_after":893,"derivative":{"underlying":"Common Stock","underlying_shares":893},"source":{"system":"sec-edgar","filing":"0001019056-21-000355","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000355/elhibri.xml","form_type":"4"}},{"id":2686611,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-02T23:33:16.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":2678,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on June 1, 2022."}],"balance_after":2678,"derivative":{"exercise_price":26.15,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":2678},"source":{"system":"sec-edgar","filing":"0001019056-21-000355","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000355/elhibri.xml","form_type":"4"}},{"id":2829183,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Unit","published_at":"2021-02-27T00:22:37.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":13906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 24, 2021, Mr. El-Hibri was granted 13,906 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 24, 2021, Mr. El-Hibri was granted 13,906 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":13906,"derivative":{"underlying":"Common Stock","underlying_shares":13906},"source":{"system":"sec-edgar","filing":"0000899243-21-008483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924321008483/doc4.xml","form_type":"4"}},{"id":2829182,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2021-02-27T00:22:37.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":27808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 24, 2021, Mr. El-Hibri was granted 27,808 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":27808,"derivative":{"exercise_price":93.49,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":27808},"source":{"system":"sec-edgar","filing":"0000899243-21-008483","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924321008483/doc4.xml","form_type":"4"}},{"id":2854809,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-18T02:00:20.000Z","date":"2020-07-02","kind":"grant","acquired":true,"shares":3571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three approximately equal annual installments beginning on July 2, 2021."}],"balance_after":3571,"derivative":{"exercise_price":9.18,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":3571},"source":{"system":"sec-edgar","filing":"0001019056-21-000140","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905621000140/elhibri.xml","form_type":"4"}},{"id":2982878,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-10","kind":"exercise","acquired":false,"shares":19391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018."}],"balance_after":0,"derivative":{"exercise_price":26.45,"expiration_date":"2022-03-09","underlying":"Common Stock","underlying_shares":19391},"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2982877,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-09","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018."}],"balance_after":19391,"derivative":{"exercise_price":26.45,"expiration_date":"2022-03-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2982876,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-10","kind":"sale","acquired":false,"shares":19391,"price":88.21,"value":1710480.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.69 to $90.00. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1123988,"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2982875,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-10","kind":"exercise","acquired":true,"shares":19391,"price":26.45,"value":512891.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."}],"balance_after":1143379,"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2982874,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":20000,"price":95.26,"value":1905200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.85 to $98.49. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1123988,"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2982873,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-12T23:30:16.000Z","date":"2020-11-09","kind":"exercise","acquired":true,"shares":20000,"price":26.45,"value":529000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."}],"balance_after":1143988,"source":{"system":"sec-edgar","filing":"0000899243-20-030866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030866/doc4.xml","form_type":"4"}},{"id":2992405,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018."}],"balance_after":39391,"derivative":{"exercise_price":26.45,"expiration_date":"2022-03-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":2992404,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The options vested in three equal installments on March 9, 2016, March 9, 2017 and March 9, 2018."}],"balance_after":59391,"derivative":{"exercise_price":26.45,"expiration_date":"2022-03-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":2992403,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":20000,"price":90.74,"value":1814800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.97 to $92.24. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1123988,"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":2992402,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":20000,"price":26.45,"value":529000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."}],"balance_after":1143988,"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":2992401,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":20000,"price":90.44,"value":1808800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.40 to $91.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1123988,"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":2992400,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-11-05T01:53:31.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":20000,"price":26.45,"value":529000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."}],"balance_after":1143988,"source":{"system":"sec-edgar","filing":"0000899243-20-030431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320030431/doc4.xml","form_type":"4"}},{"id":3022290,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-25T23:00:55.000Z","date":"2020-09-24","kind":"sale","acquired":false,"shares":12535,"price":98.85,"value":1239084.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.84 to $100.44.  The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1123988,"source":{"system":"sec-edgar","filing":"0000899243-20-026348","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320026348/doc4.xml","form_type":"4"}},{"id":3022289,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-25T23:00:55.000Z","date":"2020-09-23","kind":"sale","acquired":false,"shares":13000,"price":100.58,"value":1307540.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.86 to $102.63.  The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1136523,"source":{"system":"sec-edgar","filing":"0000899243-20-026348","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320026348/doc4.xml","form_type":"4"}},{"id":3026711,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-18T22:25:02.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":20000,"price":100.68,"value":2013600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.07 to $102.18.  The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1149523,"source":{"system":"sec-edgar","filing":"0000899243-20-025750","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320025750/doc4.xml","form_type":"4"}},{"id":3026710,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-18T22:25:02.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":20000,"price":102.48,"value":2049600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.13 to $102.27.  The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":1169523,"source":{"system":"sec-edgar","filing":"0000899243-20-025750","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320025750/doc4.xml","form_type":"4"}},{"id":3033047,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-12T01:21:56.000Z","date":"2020-09-10","kind":"sale","acquired":false,"shares":20000,"price":102.66,"value":2053200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.72 to $104.06."}],"balance_after":1189523,"source":{"system":"sec-edgar","filing":"0000899243-20-024940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320024940/doc4.xml","form_type":"4"}},{"id":3033046,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-09-12T01:21:56.000Z","date":"2020-09-09","kind":"sale","acquired":false,"shares":20000,"price":102.8,"value":2056000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.88 to $105.10."}],"balance_after":1209523,"source":{"system":"sec-edgar","filing":"0000899243-20-024940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320024940/doc4.xml","form_type":"4"}},{"id":3074041,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:18:40.000Z","date":"2020-07-27","kind":"grant","acquired":true,"shares":170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant."}],"balance_after":170,"derivative":{"exercise_price":8.56,"expiration_date":"2030-07-26","underlying":"Common Stock","underlying_shares":170},"source":{"system":"sec-edgar","filing":"0001019056-20-000436","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000436/elhibri.xml","form_type":"4"}},{"id":3074040,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:18:40.000Z","date":"2020-07-27","kind":"grant","acquired":true,"shares":1322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options vest in full on the one year anniversary of the date of grant."}],"balance_after":1322,"derivative":{"exercise_price":8.56,"expiration_date":"2030-07-26","underlying":"Common Stock","underlying_shares":1322},"source":{"system":"sec-edgar","filing":"0001019056-20-000436","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000436/elhibri.xml","form_type":"4"}},{"id":3074039,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:18:40.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":1785,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options provide for vesting in three approximately equal annual installments beginning on May 31, 2019. Prior to July 27, 2020, all but 595 shares of the issuer's common stock underlying this stock option had vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":76.86,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":1785},"source":{"system":"sec-edgar","filing":"0001019056-20-000436","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000436/elhibri.xml","form_type":"4"}},{"id":3074038,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:18:40.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":892,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options vested in three approximately equal annual installments beginning on June 1, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":30.1,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":892},"source":{"system":"sec-edgar","filing":"0001019056-20-000436","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000436/elhibri.xml","form_type":"4"}},{"id":3074037,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-30T01:18:40.000Z","date":"2020-07-27","kind":"disposition_to_issuer","acquired":false,"shares":1339,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options vested in three approximately equal annual installments beginning on August 3, 2017."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020."}],"balance_after":0,"derivative":{"exercise_price":41.16,"expiration_date":"2026-08-03","underlying":"Common Stock","underlying_shares":1339},"source":{"system":"sec-edgar","filing":"0001019056-20-000436","document":"elhibri.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905620000436/elhibri.xml","form_type":"4"}},{"id":3165065,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-05-02T00:13:03.000Z","date":"2020-04-30","kind":"sale","acquired":false,"shares":20000,"price":74.01,"value":1480200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.20 to $74.92."}],"balance_after":1229523,"source":{"system":"sec-edgar","filing":"0000899243-20-011765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320011765/doc4.xml","form_type":"4"}},{"id":3165064,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-05-02T00:13:03.000Z","date":"2020-04-29","kind":"sale","acquired":false,"shares":20000,"price":74.24,"value":1484800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.39 to $77.59."}],"balance_after":1249523,"source":{"system":"sec-edgar","filing":"0000899243-20-011765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320011765/doc4.xml","form_type":"4"}},{"id":3170027,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-24T20:16:11.000Z","date":"2020-04-23","kind":"sale","acquired":false,"shares":20000,"price":68.49,"value":1369800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.73 to $70.30."}],"balance_after":1269523,"source":{"system":"sec-edgar","filing":"0000899243-20-011283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320011283/doc4.xml","form_type":"4"}},{"id":3170026,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-24T20:16:11.000Z","date":"2020-04-22","kind":"sale","acquired":false,"shares":20000,"price":66.81,"value":1336200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.25 to $68.19."}],"balance_after":1289523,"source":{"system":"sec-edgar","filing":"0000899243-20-011283","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320011283/doc4.xml","form_type":"4"}},{"id":3172948,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-20T22:30:54.000Z","date":"2020-04-16","kind":"sale","acquired":false,"shares":20000,"price":62.47,"value":1249400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $63.83."}],"balance_after":1309523,"source":{"system":"sec-edgar","filing":"0000899243-20-011020","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320011020/doc4.xml","form_type":"4"}},{"id":3176333,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-16T01:04:05.000Z","date":"2020-04-15","kind":"sale","acquired":false,"shares":12537,"price":62.58,"value":784565.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.29."}],"balance_after":1329523,"source":{"system":"sec-edgar","filing":"0000899243-20-010812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010812/doc4.xml","form_type":"4"}},{"id":3176332,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-16T01:04:05.000Z","date":"2020-04-14","kind":"sale","acquired":false,"shares":6261,"price":62.99,"value":394380.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (\"Rule 10b5-1(c)\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.53 to $63.66."}],"balance_after":1342060,"source":{"system":"sec-edgar","filing":"0000899243-20-010812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010812/doc4.xml","form_type":"4"}},{"id":3176331,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-16T01:04:05.000Z","date":"2020-04-13","kind":"sale","acquired":false,"shares":17071,"price":62.25,"value":1062669.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (\"Rule 10b5-1(c)\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.00."}],"balance_after":1348321,"source":{"system":"sec-edgar","filing":"0000899243-20-010812","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010812/doc4.xml","form_type":"4"}},{"id":3178410,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-10T23:13:17.000Z","date":"2020-04-09","kind":"sale","acquired":false,"shares":23716,"price":61.83,"value":1466360.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.71 to $63.98."}],"balance_after":1365392,"source":{"system":"sec-edgar","filing":"0000899243-20-010651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010651/doc4.xml","form_type":"4"}},{"id":3178409,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-10T23:13:17.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":24362,"price":61.34,"value":1494365.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $62.94."}],"balance_after":1389108,"source":{"system":"sec-edgar","filing":"0000899243-20-010651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010651/doc4.xml","form_type":"4"}},{"id":3178408,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-10T23:13:17.000Z","date":"2020-04-08","kind":"sale","acquired":false,"shares":13000,"price":60.75,"value":789750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (\"Rule 10b5-1(c)\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $62.10."}],"balance_after":1413470,"source":{"system":"sec-edgar","filing":"0000899243-20-010651","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010651/doc4.xml","form_type":"4"}},{"id":3179558,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-09T01:17:32.000Z","date":"2020-04-07","kind":"sale","acquired":false,"shares":14336,"price":60.76,"value":871055.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $63.48."}],"balance_after":1426470,"source":{"system":"sec-edgar","filing":"0000899243-20-010540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010540/doc4.xml","form_type":"4"}},{"id":3179557,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-04-09T01:17:32.000Z","date":"2020-04-06","kind":"sale","acquired":false,"shares":28240,"price":60.5,"value":1708520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $61.38."}],"balance_after":1440806,"source":{"system":"sec-edgar","filing":"0000899243-20-010540","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320010540/doc4.xml","form_type":"4"}},{"id":3240805,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Unit","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-27","kind":"exercise","acquired":false,"shares":9794,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":37980,"derivative":{"underlying":"Common Stock","underlying_shares":9794},"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240804,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Unit","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-26","kind":"exercise","acquired":false,"shares":6429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":47774,"derivative":{"underlying":"Common Stock","underlying_shares":6429},"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240803,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-27","kind":"sale","acquired":false,"shares":9837,"price":56.97,"value":560413.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.25 to $58.08."}],"balance_after":1469046,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240802,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-27","kind":"tax_withholding","acquired":false,"shares":3854,"price":58.42,"value":225150.68,"ownership":{"direct":true},"balance_after":1478883,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240801,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-27","kind":"exercise","acquired":true,"shares":9794,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1482737,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240800,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":13619,"price":58.7,"value":799435.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"All sales listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.38 to $60.39."}],"balance_after":1472943,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240799,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-26","kind":"tax_withholding","acquired":false,"shares":2530,"price":59.91,"value":151572.3,"ownership":{"direct":true},"balance_after":1486562,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240798,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-26","kind":"exercise","acquired":true,"shares":6429,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1489092,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3240797,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:22.000Z","date":"2020-02-26","kind":"tax_withholding","acquired":false,"shares":2365,"price":59.91,"value":141687.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a withholding of shares by Emergent Biosolutions Inc. to satisfy tax withholding obligations on the vesting of restricted stock units pursuant to award granted February 26, 2019, which was inadvertently not reported on a Form 4 filed on February 27, 2020."}],"balance_after":1482663,"source":{"system":"sec-edgar","filing":"0000899243-20-006361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006361/doc4.xml","form_type":"4"}},{"id":3243397,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Unit","published_at":"2020-02-28T02:22:46.000Z","date":"2020-02-25","kind":"exercise","acquired":false,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":54203,"derivative":{"underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000899243-20-006083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006083/doc4.xml","form_type":"4"}},{"id":3243396,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Unit","published_at":"2020-02-28T02:22:46.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":19532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On February 25, 2020, Mr. El-Hibri was granted restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On February 25, 2020, Mr. El-Hibri was granted restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":60213,"derivative":{"underlying":"Common Stock","underlying_shares":19532},"source":{"system":"sec-edgar","filing":"0000899243-20-006083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006083/doc4.xml","form_type":"4"}},{"id":3243395,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-28T02:22:46.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":39061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 25, 2020, Mr. El-Hibri was granted 39,061 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":39061,"derivative":{"exercise_price":61.44,"expiration_date":"2027-02-24","underlying":"Common Stock","underlying_shares":39061},"source":{"system":"sec-edgar","filing":"0000899243-20-006083","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006083/doc4.xml","form_type":"4"}},{"id":3243394,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-28T02:22:46.000Z","date":"2020-02-25","kind":"exercise","acquired":true,"shares":6010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1485028,"source":{"system":"sec-edgar","filing":"0000899243-20-006083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320006083/doc4.xml","form_type":"4"}},{"id":3252404,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-21","kind":"exercise","acquired":false,"shares":18567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":0,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":18567},"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3252403,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-20","kind":"exercise","acquired":false,"shares":4751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":18567,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":4751},"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3252402,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":18567,"price":64.9,"value":1204998.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3252401,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-21","kind":"exercise","acquired":true,"shares":18567,"price":25.62,"value":475686.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1497585,"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3252400,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-20","kind":"sale","acquired":false,"shares":4751,"price":64.9,"value":308339.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3252399,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-25T01:00:20.000Z","date":"2020-02-20","kind":"exercise","acquired":true,"shares":4751,"price":25.62,"value":121720.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1483769,"source":{"system":"sec-edgar","filing":"0000899243-20-005665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005665/doc4.xml","form_type":"4"}},{"id":3262351,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-18","kind":"exercise","acquired":false,"shares":15614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":23318,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":15614},"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3262350,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-14","kind":"exercise","acquired":false,"shares":4386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":38932,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":4386},"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3262349,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":15614,"price":63.9,"value":997734.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3262348,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-18","kind":"exercise","acquired":true,"shares":15614,"price":25.62,"value":400030.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1494632,"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3262347,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":4386,"price":63.9,"value":280265.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3262346,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-20T02:00:38.000Z","date":"2020-02-14","kind":"exercise","acquired":true,"shares":4386,"price":25.62,"value":112369.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1483404,"source":{"system":"sec-edgar","filing":"0000899243-20-005195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320005195/doc4.xml","form_type":"4"}},{"id":3273496,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-06","kind":"exercise","acquired":false,"shares":11684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":63318,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":11684},"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273495,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":false,"shares":8316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":75002,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":8316},"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273494,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":83318,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273493,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":103318,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273492,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-06","kind":"exercise","acquired":true,"shares":11684,"price":25.62,"value":299344.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sale of Common Stock by the Reporting Person as reported on the Form 4 filed by the Reporting Person with the SEC on February 7, 2020."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273491,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":true,"shares":8316,"price":25.62,"value":213055.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sale of Common Stock by the Reporting Person as reported on the Form 4 filed by the Reporting Person with the SEC on February 7, 2020."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273490,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":true,"shares":20000,"price":25.62,"value":512400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."}],"balance_after":1519018,"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273489,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:33:00.000Z","date":"2020-02-05","kind":"exercise","acquired":true,"shares":20000,"price":25.62,"value":512400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission (\"SEC\") on February 7, 2020, which reported the sales of shares of the Issuer's common stock (\"Common Stock\") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises."}],"balance_after":1499018,"source":{"system":"sec-edgar","filing":"0000899243-20-004524","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004524/doc4a.xml","form_type":"4/A","original_submission_date":"2020-02-07"}},{"id":3273488,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-12","kind":"exercise","acquired":false,"shares":13720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":43318,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":13720},"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3273487,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Employee Stock Options (Right to Buy)","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-11","kind":"exercise","acquired":false,"shares":6280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested in three equal installments on March 10 2015, March 10, 2016 and March 10, 2017."}],"balance_after":57038,"derivative":{"exercise_price":25.62,"expiration_date":"2021-03-10","underlying":"Common Stock","underlying_shares":6280},"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3273486,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-12","kind":"sale","acquired":false,"shares":13720,"price":62.9,"value":862988.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3273485,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-12","kind":"exercise","acquired":true,"shares":13720,"price":25.62,"value":351506.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1492738,"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3273484,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-11","kind":"sale","acquired":false,"shares":6280,"price":62.9,"value":395012.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1479018,"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3273483,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Common Stock","published_at":"2020-02-13T23:30:38.000Z","date":"2020-02-11","kind":"exercise","acquired":true,"shares":6280,"price":25.62,"value":160893.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934."}],"balance_after":1485298,"source":{"system":"sec-edgar","filing":"0000899243-20-004522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320004522/doc4.xml","form_type":"4"}},{"id":3284138,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-02-07T23:31:56.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":11684,"price":61.9,"value":723239.6,"ownership":{"direct":true},"balance_after":1419018,"source":{"system":"sec-edgar","filing":"0000899243-20-003714","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320003714/doc4.xml","form_type":"4"}},{"id":3284137,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-02-07T23:31:56.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":48316,"price":60.66,"value":2930848.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on September 4, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $61.90."}],"balance_after":1430702,"source":{"system":"sec-edgar","filing":"0000899243-20-003714","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924320003714/doc4.xml","form_type":"4"}},{"id":3439967,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-14T01:46:26.000Z","date":"2019-08-12","kind":"purchase","acquired":true,"shares":100000,"price":0.7552,"value":75520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported on this Form 4 was made by the Reporting Person pursuant to a trading plan adopted on May 31, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.4999 to $0.8000 per share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range."}],"balance_after":1124536,"source":{"system":"sec-edgar","filing":"0001019056-19-000476","document":"elhibri.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000476/elhibri.xml","form_type":"4"}},{"id":3453297,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-30T22:49:54.000Z","date":"2019-07-29","kind":"purchase","acquired":true,"shares":55015,"price":0.8336,"value":45860.504,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8336 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.81 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":1024536,"source":{"system":"sec-edgar","filing":"0001593968-19-001685","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001685/primary_01.xml","form_type":"4"}},{"id":3456698,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-24T22:49:13.000Z","date":"2019-07-23","kind":"purchase","acquired":true,"shares":10000,"price":0.8996,"value":8996.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8996 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.89 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":969521,"source":{"system":"sec-edgar","filing":"0001593968-19-001652","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001652/primary_01.xml","form_type":"4"}},{"id":3457413,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-23T20:19:27.000Z","date":"2019-07-22","kind":"purchase","acquired":true,"shares":30000,"price":0.8867,"value":26601.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8867 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":959521,"source":{"system":"sec-edgar","filing":"0001593968-19-001649","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001649/primary_01.xml","form_type":"4"}},{"id":3458562,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-19T22:18:51.000Z","date":"2019-07-19","kind":"purchase","acquired":true,"shares":26460,"price":0.8972,"value":23739.912,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8972 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.88 to $0.90. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":929521,"source":{"system":"sec-edgar","filing":"0001593968-19-001645","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001645/primary_01.xml","form_type":"4"}},{"id":3459218,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-18T21:12:47.000Z","date":"2019-07-18","kind":"purchase","acquired":true,"shares":14404,"price":0.8745,"value":12596.298,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8745 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.89. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":903061,"source":{"system":"sec-edgar","filing":"0001593968-19-001642","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001642/primary_01.xml","form_type":"4"}},{"id":3459213,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-18T20:50:35.000Z","date":"2019-07-17","kind":"purchase","acquired":true,"shares":19136,"price":0.8729,"value":16703.8144,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8729 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.86 to $0.88. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":888657,"source":{"system":"sec-edgar","filing":"0001593968-19-001640","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001640/primary_01.xml","form_type":"4"}},{"id":3460794,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-16T21:54:56.000Z","date":"2019-07-16","kind":"purchase","acquired":true,"shares":11375,"price":0.8494,"value":9661.925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8494 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":869521,"source":{"system":"sec-edgar","filing":"0001593968-19-001632","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001632/primary_01.xml","form_type":"4"}},{"id":3462528,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Common Stock","published_at":"2019-07-12T16:41:48.000Z","date":"2019-07-11","kind":"purchase","acquired":true,"shares":14691,"price":0.8477,"value":12453.5607,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price of $0.8477 is reflective of the weighted average purchase price. The prices for the transactions reported on this line range from $0.84 to $0.85. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":858146,"source":{"system":"sec-edgar","filing":"0001593968-19-001618","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001618/primary_01.xml","form_type":"4"}},{"id":3463638,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-11T20:10:29.000Z","date":"2019-07-10","kind":"purchase","acquired":true,"shares":18919,"price":0.8488,"value":16058.4472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average price of shares purchased in multiple transactions at prices ranging from $0.845 to $0.85 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range."}],"balance_after":843455,"source":{"system":"sec-edgar","filing":"0001019056-19-000402","document":"elhibri.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000101905619000402/elhibri.xml","form_type":"4"}},{"id":3502515,"issuer":{"id":8337,"kind":"organization","name":"Aptevo Therapeutics Inc."},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false,"officer_title":"Board of Directors"}}],"security":"Option (right to buy)","published_at":"2019-06-04T17:02:19.000Z","date":"2019-06-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020."}],"balance_after":25000,"derivative":{"exercise_price":0.725,"exercise_date":"2020-06-01","expiration_date":"2029-06-01","underlying":"Aptevo Therapeutics Inc. common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001593968-19-001278","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671584/000159396819001278/primary_01.xml","form_type":"4"}},{"id":3625929,"issuer":{"id":5902,"kind":"organization","name":"Emergent BioSolutions Inc.","symbol":"EBS"},"owners":[{"id":132720,"kind":"person","name":"El-Hibri Fuad","position":1,"cik":"0001380185","reported_name":"El-Hibri Fuad","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman"}}],"security":"Restricted Stock Units","published_at":"2019-03-01T00:21:37.000Z","date":"2019-02-28","kind":"exercise","acquired":false,"shares":9722,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date."}],"balance_after":40681,"derivative":{"underlying":"Common Stock","underlying_shares":9722},"source":{"system":"sec-edgar","filing":"0000899243-19-005313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1367644/000089924319005313/doc4.xml","form_type":"4"}}],"next_cursor":"2019-03-01T00:21:37.000000Z,3625929"}